https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0310229
A double-blind, placebo-controlled, randomized, multi-centre, phase III study of MLC901...
Introduction About half of the world population will suffer from a traumatic brain injury (TBI) during their lifetime, of which about 90% of cases are mild...
https://pubmed.ncbi.nlm.nih.gov/37335674/
MLC901 in hypoxic-ischemic brain injury patients: A double-blind, randomized placebo-controlled...
MLC901 has shown, compared to placebo, a statistically better improvement at 6 months in neurological functions of patients with HIBI.